تحميل
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
76.39 US$
+0.48 US$ · +0.63%
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
الإغلاق السابق
76.39 US$
+0.48 US$ · +0.63%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
نطاق اليوم
السعر الحالي 76.39 US$
نطاق 52 أسبوعًا
السعر الحالي 76.39 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
78
أقل من القيمة
المشاعر
65
صعودي
المخاطر
20
مخاطر منخفضة
الزخم
64
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
نطاق اليوم
السعر الحالي 76.39 US$
نطاق 52 أسبوعًا
السعر الحالي 76.39 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 1.39 مليار USD | 1.25 مليار USD | 1.15 مليار USD | 1.02 مليار USD | 1.04 مليار USD |
| تكلفة البضاعة المباعة | 448.2 مليون USD | 382.56 مليون USD | 382.3 مليون USD | 314.58 مليون USD | 329.37 مليون USD |
| الربح الإجمالي | 939.9 مليون USD | 870.87 مليون USD | 771.25 مليون USD | 707.23 مليون USD | 705.99 مليون USD |
| البحث والتطوير | 185.8 مليون USD | 182.51 مليون USD | 193.82 مليون USD | 155.81 مليون USD | 183.41 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 548.8 مليون USD | 526.27 مليون USD | 518.13 مليون USD | 469.24 مليون USD | 471.9 مليون USD |
| نفقات التشغيل | 740.5 مليون USD | 741.82 مليون USD | 839.75 مليون USD | 783.98 مليون USD | 706.78 مليون USD |
| دخل الفوائد | 18.98 مليون USD | 30.08 مليون USD | 22.01 مليون USD | 4.7 مليون USD | 435 ألف USD |
| مصاريف الفوائد | 49.29 مليون USD | 63.07 مليون USD | 58.85 مليون USD | 48.25 مليون USD | 50.15 مليون USD |
| الاستهلاك والإطفاء | 42 مليون USD | 51.14 مليون USD | 60.86 مليون USD | 57.8 مليون USD | 67.99 مليون USD |
| الدخل التشغيلي | 199.4 مليون USD | 129.05 مليون USD | −68.5 مليون USD | −76.75 مليون USD | −784 ألف USD |
| صافي الدخل | −242.5 مليون USD | 63.23 مليون USD | 17.55 مليون USD | −86.25 مليون USD | −135.82 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Avantis U.S. Small Cap Value ETFAVUV121.89 مليون0.39%30.85 مليار USD0.25%119.64 US$-0.41%
iShares Russell 2000 ETFIWM111.96 مليون0.14%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF50.94 مليون0.05%95.4 مليار USD0.05%235 US$+0.80%
Dimensional - US Targeted Value ETFDFAT39.96 مليون0.13%30.12 مليار USD0.33%67.27 US$-0.43%
Invesco S&P MidCap Momentum ETFXMMO34.99 مليون0.49%7.14 مليار USD0.34%148.79 US$+0.96%
Dimensional - US Small Cap ETFDFAS32.13 مليون0.10%33.87 مليار USD0.31%78.35 US$+0.32%
Invesco S&P MidCap Quality ETFXMHQ31.56 مليون0.58%5.44 مليار USD0.30%114.23 US$+0.50%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY31.07 مليون0.12%25.82 مليار USD0.23%669.87 US$+0.54%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATInvesco S&P MidCap Momentum ETFXMMODimensional - US Small Cap ETFDFASInvesco S&P MidCap Quality ETFXMHQState Street SPDR S&P MIDCAP 400 ETF TrustMDYالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
